A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Acute Myelogenous Leukemia in Relapse Acute Myelogenous Leukemia, Relapsed, Adult Acute Myelogenous Leukemia, Adult Acute Myelogenous Leukemia High Risk Myelodysplasia AML MDS Leukemia Acute Myeloid Leukemia Aptose APTO-253 Kinase Inhibitor Leukemia, Myeloid Leukemia, Myeloid, Acute Preleukemia Myelodysplastic Syndromes Dose Escalation and Expansion
Lead Scientist at UC Irvine
- Deepa Jeyakumar, MD
Associate Clinical Professor, Medicine. Authored (or co-authored) 8 research publications.